The overexpression of N-cadherin in stages III–IV (39.58%) was higher than that in stages I (31.58%) and II (23.53%, P<0.01); N-cadherin expression in poor differentiated (64.10%) cancer tissues was higher than that in well and moderate differentiated cancer tissues (16.0% and 35.71%, P<0.01). Here, CDH2 is linked to cancer.